Key result
End-stage failing myocardium exhibits ~58% higher NADPH oxidase activity than nonfailing myocardium.
Why the study?
It was unknown whether NADPH oxidase is expressed in human myocardium or if it contributes to reactive oxygen species production in human heart failure.
Observational (n=22)
Absolute Event Rate: 5.86% vs 3.72%
p-value: p=<0.01
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Heymes et al. provided the first evidence for a lack of changes in the expression of Nox2 but an increase in the activity of [NADPH oxidase in the failing human heart]”
Hypothesis-generating for NADPH oxidase inhibition in heart failure; leaves open need for clinical outcome trials.
OBJECTIVES: This study was designed to investigate whether nicotinamide adenine dinucleotide 3-phosphate (reduced form) (NADPH) oxidase is expressed in the human heart and whether it contributes to reactive oxygen species (ROS) production in heart failure. BACKGROUND: A phagocyte-type NADPH oxidase complex is a major source of ROS in the vasculature and is implicated in the pathophysiology of hypertension and atherosclerosis. An increase in myocardial oxidative stress due to excessive production of ROS may be involved in the pathophysiology of congestive heart failure. Recent studies have suggested an important role for myocardial NADPH oxidase in experimental models of cardiac disease. However, it is unknown whether NADPH oxidase is expressed in the human myocardium or if it has any role in human heart failure. METHODS: Myocardium of explanted nonfailing (n = 9) and end-stage failing (n = 13) hearts was studied for the expression of NADPH oxidase subunits and oxidase activity. RESULTS: The NADPH oxidase subunits p22(phox), gp91(phox), p67(phox), and p47(phox) were all expressed at messenger ribonucleic acid and protein level in cardiomyocytes of both nonfailing and failing hearts. NADPH oxidase activity was significantly increased in end-stage failing versus nonfailing myocardium (5.86 +/- 0.41 vs. 3.72 +/- 0.39 arbitrary units; p < 0.01). The overall level of oxidase subunit expression was unaltered in failing compared with nonfailing hearts. However, there was increased translocation of the regulatory subunit, p47(phox), to myocyte membranes in failing myocardium. CONCLUSIONS: This is the first report of the presence of NADPH oxidase in human myocardium. The increase in NADPH oxidase activity in the failing heart may be important in the pathophysiology of cardiac dysfunction by contributing to increased oxidative stress.
No takes yet. Share an insight, caveat, or question.
Heymes et al. (2003) conducted an observational in Heart failure (n=22). End-stage heart failure vs. Nonfailing hearts was evaluated on NADPH oxidase activity (arbitrary units) (p=<0.01). End-stage failing human myocardium exhibited significantly higher NADPH oxidase activity compared to nonfailing myocardium (5.86 vs. 3.72 arbitrary units; p<0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: